Literature DB >> 8621800

Cellular bioenergetics after erythropoietin therapy in chronic renal failure.

R M Marrades1, J Alonso, J Roca, J M González de Suso, J M Campistol, J A Barberá, O Diaz, J V Torregrosa, J R Masclans, R Rodríguez-Roisin, P D Wagner.   

Abstract

After erythropoietin (rHuEPO) therapy, patients with chronic renal failure (CRF) do not improve peak O2 uptake (VO2 peak) as much as expected from the rise in hemoglobin concentration ([Hb]). In a companion study, we explain this phenomenon by the concurrent effects of fall in muscle blood flow after rHuEPO and abnormal capillary O2 conductance observed in CRF patients. The latter is likely associated with a poor muscle microcirculatory network and capillary-myofiber dissociation due to uremic myopathy. Herein, cellular bioenergetics and its relationships with muscle O2 transport, before and after rHuEPO therapy, were examined in eight CRF patients (27 +/- 7.3 [SD] yr) studied pre- and post-rHuEPO ([Hb] = 7.8 +/- 0.7 vs. 11.7 +/- 0.7 g x dl-1) during an incremental cycling exercise protocol. Eight healthy sedentary subjects (26 +/- 3.1 yr) served as controls. We hypothesize that uremic myopathy provokes a cytosolic dysfunction but mitochondrial oxidative capacity is not abnormal. 31P-nuclear magnetic resonance spectra (31P-MRS) from the vastus medialis were obtained throughout the exercise protocol consisting of periods of 2 min exercise (at 1.67 Hz) at increasing work-loads interspersed by resting periods of 2.5 min. On a different day, after an identical exercise protocol, arterial and femoral venous blood gas data were obtained together with simultaneous measurements of femoral venous blood flow (Qleg) to calculate O2 delivery (QO2leg) and O2 uptake (VO2leg). Baseline resting [phosphocreatine] to [inorganic phosphate] ratio ([PCr]/[Pi]) did not change after rHuEPO (8.9 +/- 1.2 vs. 8.8 +/- 1.2, respectively), but it was significantly lower than in controls (10.9 +/- 1.5) (P = 0.01 each). At a given submaximal or peak VO2leg, no effects of rHuEPO were seen on cellular bioenergetics ([PCr]/[Pi] ratio, %[PCr] consumption halftime of [PCr] recovery after exercise), nor in intracellular pH (pHi). The post-rHuEPO bioenergetic status and pHi, at a given VO2leg, were below those observed in the control group. However, at a given pHi, no differences in 31P-MRS data were detected between post-rHuEPO and controls. After rHuEPO, at peak VO2, Qleg fell 20% (P < 0.04), limiting the change in QO2leg to 17%, a value that did not reach statistical significance. The corresponding O2 extraction ratio decreased from 73 +/- 4% to 68 +/- 8.2% (P < 0.03). These changes indicate that maximal O2 flow from microcirculation to mitochondria did not increase despite the 50% increase in [Hb] and explain how peak VO2leg and cellular bioenergetics (31P-MRS) did not change after rHuEPO. Differences in pHi, possibly due to lactate differences, between post-rHeEPO and controls appear to be a key factor in the abnormal muscle cell bioenergetics during exercise observed in CRF patients.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8621800      PMCID: PMC507285          DOI: 10.1172/JCI118647

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  34 in total

Review 1.  Diffusion and chemical reaction in pulmonary gas exchange.

Authors:  P D Wagner
Journal:  Physiol Rev       Date:  1977-04       Impact factor: 37.312

2.  Spirometric reference values from a Mediterranean population.

Authors:  J Roca; J Sanchis; A Agusti-Vidal; F Segarra; D Navajas; R Rodriguez-Roisin; P Casan; S Sans
Journal:  Bull Eur Physiopathol Respir       Date:  1986 May-Jun

3.  Effects of erythropoietin on muscle O2 transport during exercise in patients with chronic renal failure.

Authors:  R M Marrades; J Roca; J M Campistol; O Diaz; J A Barberá; J V Torregrosa; J R Masclans; A Cobos; R Rodríguez-Roisin; P D Wagner
Journal:  J Clin Invest       Date:  1996-05-01       Impact factor: 14.808

4.  Bioenergetics of intact human muscle. A 31P nuclear magnetic resonance study.

Authors:  D J Taylor; P J Bore; P Styles; D G Gadian; G K Radda
Journal:  Mol Biol Med       Date:  1983-07

5.  Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. Results of a combined phase I and II clinical trial.

Authors:  J W Eschbach; J C Egrie; M R Downing; J K Browne; J W Adamson
Journal:  N Engl J Med       Date:  1987-01-08       Impact factor: 91.245

Review 6.  Recombinant human erythropoietin: implications for nephrology.

Authors:  J W Eschbach; J W Adamson
Journal:  Am J Kidney Dis       Date:  1988-03       Impact factor: 8.860

7.  The anemia of chronic renal failure in sheep. Response to erythropoietin-rich plasma in vivo.

Authors:  J W Eschbach; J Mladenovic; J F Garcia; P W Wahl; J W Adamson
Journal:  J Clin Invest       Date:  1984-08       Impact factor: 14.808

8.  Evidence for tissue diffusion limitation of VO2max in normal humans.

Authors:  J Roca; M C Hogan; D Story; D E Bebout; P Haab; R Gonzalez; O Ueno; P D Wagner
Journal:  J Appl Physiol (1985)       Date:  1989-07

9.  Hemodynamic changes by recombinant erythropoietin therapy in hemodialyzed patients.

Authors:  K Satoh; T Masuda; Y Ikeda; S Kurokawa; K Kamata; R Kikawada; T Takamoto; F Marumo
Journal:  Hypertension       Date:  1990-03       Impact factor: 10.190

10.  Long-term cardiorespiratory effects of amelioration of renal anaemia by erythropoietin.

Authors:  I C Macdougall; N P Lewis; M J Saunders; D L Cochlin; M E Davies; R D Hutton; K A Fox; G A Coles; J D Williams
Journal:  Lancet       Date:  1990-03-03       Impact factor: 79.321

View more
  3 in total

1.  Skeletal Muscle Mitochondrial Dysfunction Is Present in Patients with CKD before Initiation of Maintenance Hemodialysis.

Authors:  Jorge L Gamboa; Baback Roshanravan; Theodore Towse; Chad A Keller; Aaron M Falck; Chang Yu; Walter R Frontera; Nancy J Brown; T Alp Ikizler
Journal:  Clin J Am Soc Nephrol       Date:  2020-06-26       Impact factor: 8.237

2.  Impaired skeletal muscle mitochondrial bioenergetics and physical performance in chronic kidney disease.

Authors:  Bryan Kestenbaum; Jorge Gamboa; Sophia Liu; Amir S Ali; Eric Shankland; Thomas Jue; Cecilia Giulivi; Lucas R Smith; Jonathan Himmelfarb; Ian H de Boer; Kevin Conley; Baback Roshanravan
Journal:  JCI Insight       Date:  2020-03-12

3.  Chronic kidney disease induces a systemic microangiopathy, tissue hypoxia and dysfunctional angiogenesis.

Authors:  Hans-Ulrich Prommer; Johannes Maurer; Karoline von Websky; Christian Freise; Kerstin Sommer; Hamoud Nasser; Rudi Samapati; Bettina Reglin; Pedro Guimarães; Axel Radlach Pries; Uwe Querfeld
Journal:  Sci Rep       Date:  2018-03-28       Impact factor: 4.379

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.